Doctors at Fortis Memorial Research Institute (FMRI), Gurugram, have reported remarkable success in treating children with Sickle Cell Disease (SCD) using stem cell transplantation. This achievement positions India among the top countries in pediatric transplant outcomes.
The decade-long study, published in the international journal Haemoglobin, covered 100 pediatric cases treated between 2015 and 2024. The study found:
These figures rank among the best worldwide and represent a significant step forward in managing SCD in developing countries.
The study emphasized the importance of early diagnosis and timely transplantation. Conducting the procedure before serious complications like stroke or organ damage occur greatly enhances the chances of long-term survival.
Fortis used specialized transplant methods that reduce side effects and lower the risk of Graft-versus-Host Disease (GVHD), a frequent post-transplant complication.
"Performing the procedure before severe complications such as stroke or organ damage dramatically improves outcomes."
"These results rank among the best reported globally, marking a significant advancement in the management of Sickle Cell Disease in developing nations."
Fortis continues to deliver world-class, life-saving care at a fraction of global costs, standing alongside the best international centers.
Author's summary: Fortis Gurugram's decade-long research demonstrates world-class success in pediatric stem cell transplants for Sickle Cell Disease, underscoring early intervention and advanced protocols as keys to improved survival.